Sanofi Korea has granted Mitsubishi Tanabe Pharma Korea exclusive rights to market its multiple sclerosis (MS) pill Aubagio in the country, according to a Monday announcement.

The arrangement, effective Sept. 1, gives Mitsubishi Tanabe control of sales and marketing, while Sanofi retains responsibility for import, supply and regulatory management.

Aubagio, or teriflunomide, is an oral, once-daily therapy approved for relapsing forms of MS and already widely used in global markets.